GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Total Assets

Tryptamine Therapeutics (ASX:TYP) Total Assets : A$3.08 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics Total Assets?

Tryptamine Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was A$3.08 Mil.

During the past 12 months, Tryptamine Therapeutics's average Total Assets Growth Rate was -90.20% per year. During the past 3 years, the average Total Assets Growth Rate was -4.10% per year. During the past 5 years, the average Total Assets Growth Rate was 64.50% per year.

During the past 6 years, Tryptamine Therapeutics's highest 3-Year average Total Assets Growth Rate was 151.90%. The lowest was -4.10%. And the median was 107.40%.

Total Assets is connected with ROA %. Tryptamine Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -71.89%. Total Assets is also linked to Revenue through Asset Turnover. Tryptamine Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Tryptamine Therapeutics Total Assets Historical Data

The historical data trend for Tryptamine Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Total Assets Chart

Tryptamine Therapeutics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Assets
Get a 7-Day Free Trial 5.40 6.54 21.46 13.61 5.88

Tryptamine Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 14.65 13.61 7.12 5.88 3.08

Tryptamine Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Tryptamine Therapeutics's Total Assets for the fiscal year that ended in Jun. 2023 is calculated as

Total Assets=Total Equity (A: Jun. 2023 )+Total Liabilities (A: Jun. 2023 )
=4.127+1.754
=5.88

Tryptamine Therapeutics's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (Q: Dec. 2023 )+Total Liabilities (Q: Dec. 2023 )
=2.715+0.368
=3.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tryptamine Therapeutics  (ASX:TYP) Total Assets Explanation

Total Assets is connected with ROA %.

Tryptamine Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-3.222/( (5.881+3.083)/ 2 )
=-3.222/4.482
=-71.89 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Tryptamine Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is

Asset Turnover
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (5.881+3.083)/ 2 )
=0/4.482
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Tryptamine Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics (ASX:TYP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Total Assets
Comparable Companies
ASX:NC6 ASX:ILA ASX:HXL ASX:ANR ASX:NYR ASX:RGS ASX:NSB ASX:1AD ASX:ZLD ASX:MEM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124
Website
https://www.exopharm.com
Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

Tryptamine Therapeutics (ASX:TYP) Headlines

No Headlines